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1 INTRODUCTION  
 Microbubbles are gas filled microspheres which are approved for diagnostic 
ultrasound contrast imaging by the FDA. Such bubbles, a few microns in size, are 
usually filled with an hydrophobic gas and are stabilized by a surfactant (lipid, protein 
or polymer) shell, to enhance their shelf life and circulation time in blood after 
injection. Because of the difference in density between the gas core of the 
microbubble and the surrounding fluid, microbubbles start to oscillate when subjected 
to high frequency (1-10 MHz) ultrasound. This “cavitation” of microbubbles has been 
intensively studied by means of high speed optical imaging [1-3] and can be divided 
into respectively stable and inertial cavitation. In an ultrasound field with a low 
acoustical pressure microbubbles are stably cavitating and will oscillate around a 
given diameter. Inertial cavitation on the other hand occurs at higher acoustical 
pressures, the movement of the microbubbles becomes more violent which leads to 
destruction of the microbubbles [4]. This microbubble destruction produces distinct 
nonlinear acoustic echoes which are very useful in contrast enhanced ultrasound 
imaging [5]. Cavitation of microbubbles may also induce biological and mechanical 
effects on the surrounding space which may be particularly useful for drug delivery 
[6]. 
When microbubble collapse occurs in the vicinity of cells it has been shown 
that plasma membranes are temporarily permeabilized through the formation of 
transient pores in the cellular membrane, induced by micro-jets and shockwaves 
produced after microbubble collapse [3,7]. This phenomenon is called sonoporation 
[6]. It is believed that sonoporation is strongly dependent on the acoustical properties 
of the applied ultrasound field [8,9]. Such transient pores also enhance the uptake of 
macromolecules in cells [10]. Recent studies show that sonoporation effects may last 
up to 24 hours after ultrasound treatment [11]. The use of microbubbles in 
combination with ultrasound may even induce openings in the blood-brain barrier 
which could be of interest to tackle drug delivery into the brain which currently 
remains a huge challenge [12,13]. 
 Only if the drug molecules are physically located in the vicinity of microbubbles 
subjected to ultrasound, it is expected that sonoporation will enhance drug uptake by 
cells. Moreover, as these effects will only occur where and when ultrasound is 
applied, drug delivery is expected only to happen in the insonated tissue. Hence, for 
ultrasound targeted drug delivery it is crucial to design microbubbles which can be 
loaded with drug molecules. Meanwhile a number of concepts for drug loaded 
microbubbles are under investigation [14-16]. Basically, microbubbles can be loaded 
with drugs in three ways: (a) the drug can be incorporated in the microbubble shell 
[17], (b) (lipophilic) drugs can be incorporated in an inner oil phase present in the 
microbubbles [18] or (c) “colloidally drug loaded microbubbles” can be obtained 
through the attachement of drug containing nanoparticles (like e.g. liposomes) on the 
microbubbles‟ surface as reviewed by Bohmer et al. and Lentacker et al [19,20]. 
Independent on the way the microbubbles become loaded with drugs, they should 
fulfill at least the following requirements: (a) the microbubbles should be loaded with 
a sufficient amount of drug; (b) the shelf-life of the drug-loaded microbubbles should 
be long enough and (c) the drug-loaded microbubbles should be designed without 
the incorporation of toxic or immunogenic substances. We believe that loading the 
surface of microbubbles with drug containing liposomes is a promising concept for 
ultrasound guided drug delivery as: (a)more drugs can be loaded on microbubbles 
compared with other loading strategies, (b) a plethora of knowledge is available on 
liposomes for drug delivery which can be perfectly used to develop the colloidally 
loaded microbubble concept and (c) importantly, certain liposomes are safe and even 
already used in clinical practice. 
Recently we succeeded in preparing respectively doxorubicin (DOX)-liposome 
loaded microbubbles [21] and lipoplex-loaded microbubbles (containing pDNA or 
siRNA). We showed that in combination with ultrasound, such microbubbles strongly 
improved both doxorubicin (DOX) cytotoxicity and pDNA [16,22] and siRNA [23] 
delivery to cells in vitro. However, the complex microbubble preparation method, the 
immunogenic nature of the avidin-biotin chemistry used to link the 
liposomes/lipoplexes to the microbubbles and the successive washing steps, made 
this material not ideal for easy clinical use. It is clear that the concept of liposome-
/lipoplex-loaded microbubbles needs further development and improvement. In this 
work we faced the challenge to design DOX-liposome loaded lipid shelled 
microbubbles through the self-assembly of the involved compounds. Importantly, the 
method we propose involves just a single step and allows to make a sterile material. 
As illustrated in Figure 1 and further explained in the results section, to a mixture of 
phospholipids, so named “functionalized DOX-liposomes” (i.e. DOX-liposomes 
containing MALEIMIDE functionalized PEG-lipids) and a hydrophobic gas were 
added. We show that under appropriate conditions these compounds self-assemble 
into DOX-liposome loaded microbubbles which are responsive to ultrasound and 
efficiently kill cells.  
 
 
 
 Figure 1: Schematic depiction of the preparation of liposome-loaded 
through self-assembly of the different constituents: Drug loaded liposomes 
containing DSPE-PEG-MALEIMIDE and perfluorobutane (C4F10) gas were added to 
vials containing: DPPC and DSPE-PEG-SPDP dissolved in a 
glycerin:propyleneglycol:H2O mixture (A) and were mechanically activated using a 
Capmix™ device. This mechanical activation gives rise to lipid-shelled microbubbles 
(B) loaded with liposomes. These microbubbles are filled with the hydrophobic C4F10 
gas (C). The liposomes become coupled to the microbubbles‟ surface through 
covalent thiol-maleimide linkages (D). Note that the microbubbles are a few microns 
in size while the liposomes are some hundreds of nanometers. 
2 MATERIALS AND METHODS 
2.1 Preparation and characterization of functionalized microbubbles 
“Functionalized microbubbles” (i.e. microbubbles containing thiol-functionalized 
PEG-lipids) were prepared starting from a lipid solution being a mixture of 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[PDP(polyethylene glycol)-2000] (DSPE-PEG-PDP) (Avanti 
polar lipids, Albaster, AL) in a 1:2:7 glycerine-propyleneglycol-H2O solvent (Sigma-
aldrich,Bornem,Belgium); the molar ratio of the lipids in the lipid solutions was 
respectively 97:3, 92:8 and 65:35. The lipid solution was prepared as follows. 
Aliquots of both lipids, dissolved in CHCL3, were transferred into a round bottom 
flask. After CHCl3 evaporation, the lipid film was dissolved in a 1:2:7 glycerine-
propyleneglycol-H2O mixture to obtain a clear solution with a final lipid concentration 
of 4 x 10-4 mmol/ml (or 2 x 10-4 mmol/ml for microbubbles used in the cell 
experiments). Aliquots of this lipid solution were transferred into 2.5 ml 
chromatography vials, which headspace was filled with C4F10 gas (F2 chemicals, 
Preston, UK). Finally, functionalized microbubbles (with an average size of 3µm) 
were obtained by high speed shaking of the lipid solution in a Capmix™ device (3M-
ESPE, Diegem, Belgium) during 15 sec. The size and the concentration of the 
microbubbles in the dispersion (i.e. number of microbubbles per mL) were 
determined with a Beckman-coulter Multisizer 4 (Beckman-coulter, Brea, CA) 
2.2 Preparation of non-functionalized microbubbles 
Preparation of so named “non-functionalized microbubbles” occurred as 
described above for the functionalized bubbles, however 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DSPE-MPEG) (Avanti 
polar lipids, Albaster, AL) was used as a PEG-lipid instead of DSPE-PEG-PDP.  
2.3 Preparation and characterization of bodipy-labeled and DOX-liposomes 
Bodipy-labeled liposomes were prepared by transferring DPPC, DSPE-PEG-
MALEIMIDE) (Avanti polar lipids, Albaster, AL), cholesterol (Sigma-alldrich, Bornem, 
Belgium) and cholesteryl-bodipy (Invitrogen, Merelbeke, Belgium), all dissolved in 
CHCl3, in a 49:15:35:1 molar ratio to a round bottom flask. After CHCl3 evaporation, 
the remaining lipid film was rehydrated with HEPES buffer (50 mM, pH 7.4, Sigma-
alldrich, Bornem, Belgium) to obtain a liposomal dispersion with a final lipid 
concentration of 16 mg/ml. The liposomal dispersion was hereafter extruded through 
a 200 nm filter using a mini-extruder at 60 °C (Avanti polar lipids, Albaster, AL).  
DOX-liposomes were prepared as described by lentacker et al [21]. Briefly, 
DPPC, DSPE-PEG-MALEIMIDE and cholesterol dissolved in CHCl3 at a 
concentration of 20 mg/ml and 10 mg/ml respectively, were transferred in a round 
bottom flask in a 49:15:36 molar ratio. After evaporation the remaining lipid film was 
rehydrated with ammonium sulfate buffer (250 mM) to obtain a liposomal dispersion 
with a final lipid concentration of 16 mg/ml. The resulting liposome dispersion was 
extruded through a 200 nm filter using a mini-extruder at 60 °C. After extrusion the 
excess of ammonium sulfate was removed by overnight dialysis against distilled 
water (MWCO: 8000 Da, Spectra/Por Biotech, Compton, CA). Hereafter the 
liposomal dispersion was aliquoted into 450 µl aliquots and liposomes were loaded 
with DOX by adding 50 µl of a doxorubicin.HCl (Sigma-alldrich, Bornem, Belgium) 10 
mg/ml solution. Non-encapsulated DOX was removed in a second overnight dialysis 
against distilled water. Final DOX concentration was evaluated using absorbance 
spectrometry using an Envision plate-reader and reached between 0.5 and 0.8 mg/ml 
(Perkin-elmer, Waltham, MA) 
2.4 Preparation of liposome-loaded microbubbles 
Liposome-loaded microbubbles were prepared by adding a certain volume of 
the liposome dispersion to the lipid solution used for the preparation of microbubbles 
(see above, under 1.1 and 1.2). Liposome-loaded microbubbles were obtained by 
high-speed shaking of this liposome/lipid mixture in a Capmix™ device. The loading 
of the microbubbles with (bodipy-containing) liposomes was visualized using a Nikon 
EZC1 confocal microscope equipped with a 60x lens imaging using the 490 nm 
excitation light, while fluorescence was detected at 551 nm.  
2.5 Evaluation of the loading of the microbubbles with liposomes by flow 
cytometry 
How different parameters influence the loading of microbubbles with bodipy-
labeled liposomes was determined using a flow cytometer (BD FACScalibur, 
Erembodegem, Belgium). Herefore 300 µl of (bodipy-) liposome-loaded microbubbles 
were diluted in 300 µl of HEPES buffer. The 488 nm laser of the flow cytometer was 
used to excite the bubbles while the emitted fluorescence was detected in the 530 
nm channel FL1. Results were expressed as mean fluorescence per microbubble 
using unloaded microbubbles as a blank. For measurements on microbubbles in 
plasma, platelet poor plasma was obtained by centrifuging whole blood samples first 
at 300 g for 10 min and subsequently at 3200 g for 10 min. 20 µl of (bodipy-) 
liposome-loaded microbubbles were suspended in 150 µl of plasma and diluted with 
200 µl Hepes buffer. All the flow cytometry experiments were performed in triplicate 
and the presented data are the mean values. 
2.6 Evaluation of the loading of the microbubbles with liposomes by Coulter 
Counter measurements 
The loading of the microbubbles with liposomes was further studied by the 
electrical sensing zone method with a Beckman-Coulter Multisizer 4 Coulter Counter. 
For each Coulter Counter experiment 20 µl of (liposome-loaded) microbubbles were 
diluted in 10 ml of Phosphate Buffered Saline (PBS, GIBCO, Merelbele, Belgium); 50 
µl of this dilution was applied in the Multisizer 4 which was equipped with a 20 µm 
aperture tube. The liposome-loaded microbubbles used in the Coulter Counter 
experiments were obtained by transferring 1 ml of lipid solution (lipid concentration: 4 
x 10-4 mmol/ml) and respectively 0, 35, 100 and 200 µl bodipy liposomes into a 2.5 ml 
chromatography vial, followed by high-speed shaking in the Capmix™ device.  
 We determined respectively the number of (unloaded and liposome-loaded) 
microbubbles per mL and the volume of all bubbles present in 1 ml of dispersion (i.e. 
“total volume per ml”). The volume of a single microbubble could then be determined 
by equation (1).  
(1)                   
                  
                        
 
The volume increase of a microbubble upon loading with lipsosomes (i.e. “liposome 
volume per bubble”) could be calculated by equation (2) below.  
(2)l                          
                                                       ) 
Dividing this liposome volume per microbubble by the volume of a single 
(spherical) liposome (with an average diameter of approximately 200 nm as was 
determined by dynamic light scattering) gives an estimation of the amount of 
liposomes loaded on one microbubble (equation 3). 
(3)                                
                              
                       
 
All measurements were performed at least in triplicate and results are 
presented as the mean of three different measurements. 
2.7 Ultrasound induced DOX-release 
The release of doxorubicin from the liposomes was determined by fluorescence 
measurements. The following samples were prepared for the release experiments. 
One ml of lipid solution was mixed with 10 or 20 µl of DOX-liposomes with a DOX-
concentration of 0.1 mg/ml and C4F10 gas. After shaking the lipid/lipsome mixture in 
the Capmix™ device the mixture was diluted with PBS to a final volume of 10 ml and 
injected in an OpticellTM (Biocrystal, Westerville, OH) plate. This plate was 
submerged in a water bath (37°C) with an absorbing rubber and subjected to 
ultrasound during 15 s using the Sonitron device (Artison Corporation, Inola, OK, 
USA) equipped with a 2 cm ultrasound probe[22,24]. This probe was used with an 
ultrasound frequency of 1 MHz with 20 % duty cycle at an ultrasound intensity of 2 
W/cm2. Subsequently, the fluorescence of each sample was measured in a Wallac 
envision plate reader (λexc 500 nm, λem 550 nm). Each experiment was performed at 
least in triplicate. 
2.8 Cell culture and cytotoxicity tests 
BLM cells [24] (melanoma cells) were cultured in F12-supplemented Dulbecco‟s 
modified Eagles medium (DMEM-F12) which contained 1% Penicilin/Streptomycin, 
2mmol/l glutamine, 10 % Fetal bovine serum (FBS) (all purchased from Gibco, 
Merelbeke, Belgium) and 100 mmol/l HEPES pH 7.2. Cells were grown in an 
humidified incubator at 37°C in a 5 % CO2 atmosphere. 
BLM cells were seeded in Opticell™ plates  (1.3 x 106 cells per Opticell™) and 
were grown to 90 % confluency, which was reached two days after seeding. Before 
experiments were performed, cells were washed with PBS. Subsequently, DOX-
liposome loaded microbubbles were added to the cells. The following samples were 
prepared for the cytotoxicity experiments. To 500 µl of lipid solution (lipid 
concentration of 2 x 10-4 mmol/ml) respectively 10, 100, 250 or 500 µl of DOX 
liposomes (with a DOX concentration of 0.54 mg/ml) were added; HEPES-buffer (50 
mM, pH 7.4) was added until a final volume of 1 ml was reached. Before shaking 
vials were filled with C4F10 gas. After shaking in the Capmix™ device, the 1 ml 
microbubble dispersion was added to 10 ml of optimem and this mixture was added 
to the cells in Opticell™ plates. Subsequently, these plates were submerged in a 
warm water bath (37°C) with a bottom of ultrasound absorbing rubber. Ultrasound 
was delivered by moving the Sonitron ultrasound probe over the whole plate during 
10-15 sec. We used 1 MHz ultrasound with a 20 % duty cycle with an ultrasound 
intensity of 2 W/cm2. During ultrasound application cells were located on the top 
membrane of the Opticell™, in this way microbubbles are directly contacting the cells 
during sonication. After ultrasound application cell displacement was evaluated by 
means of microscopy and was always minimal with the microbubble concentrations 
used for these experiments. 
 After 4 hours of incubation, microbubbles were removed, cells were washed 
with PBS and incubated in fresh culture medium. After 24 hours cells were washed 
and the MTT reagent (Cell proliferation kit I, Roche diagnostics, Leuven, Belgium) 
was added for 4 hours. Subsequently, the sollubilization reagent was added and cells 
were incubated overnight to allow cell lysis at 37°C. The next day, the absorbance of 
each plate was measured in an absorbance plate reader at respectively 590 nm 
(OD590) to determine the formed formazan and at 690 nm (OD690) as a reference. The 
results of the cytotoxicity measurements are expressed as percentages; the viability 
of the cells which were only treated with optimem was considered to be 100 %, while 
the viability of cells exposed to phenol was considered to be 0 %. Experiments were 
performed at least in triplicate. 
2.9 Statistical analysis 
All data are presented as means +/- one standard deviation. A student‟s t-test 
was performed to determine whether datasets differed significantly. A p-value smaller 
than 0.05 was regarded significant. 
3 RESULTS 
3.1 Preparation of liposome-loaded microbubbles by self-assembly  
As schematically presented in Figure 1, to make liposome-loaded 
microbubbles, to a mixture of the (functionalized) lipids DPPC and DSPE-PEG-
SPDP, dissolved in a glycerine-propyleneglycol-water solvent at a concentration 
below their critical micellar concentration [25], liposomes containing DSPE-PEG-
MALEIMIDE were added. We observed that liposomes dispersed in the lipid solution 
are stable and can be stored during at least several weeks (data not shown). 
Therefore we stored the liposome/lipid dispersion at 4°C in chromatography vials. To 
“activate” the mixture, which refers to (as formation of liposome loaded microbubbles 
(Figure 1C), the vials‟ headspaces were filled with perfluorobutane gas and 
subsequently mixed with a high speed shaking-device (Capmix™ or Vialmix™). The 
Capmix™ disperses the lipophilic perfluorobutane in the lipid solution. Hence, the 
hydrophobic tales of the dissolved lipids interact with the dispersed gas and stabilize 
the gas bubbles formed. Because functionalized (SPDP-) PEG-lipids were used 
which can interact with the functionalized (MALEIMIDE-)PEG-lipids of the liposomes 
(Figure 1D), liposome-loaded microbubbles were spontaneously formed during this 
process as can be seen in the confocal image in Figure 2B and its corresponding 
transmission image (Figure 2A) clearly show bodipy-labeled liposomes at the surface 
of the microbubbles.  
 
Figure 2: microscopy and Coulter Counter studies of liposome-loaded 
microbubbles: Transmission image (A) and confocal image (B) of a (bodipy-labeled) 
liposome-loaded microbubble. Size distributions of unloaded and liposome loaded 
microbubbles as obtained by Coulter Counter measurements (C) show an increase in 
mean size when liposomes are bound to the microbubbles‟ surface. 
Subsequently we measured the size distribution and microbubble concentration 
of respectively unloaded and loaded microbubbles by Coulter Counter (Figure 2C). 
The unloaded microbubbles showed an average volume diameter of 3.6 µm while the 
diameter of liposome-loaded microbubbles equaled 4.0 µm. The microbubble 
dispersions contained respectively 1.23 x109 (unloaded) and 1.04 x 109 (loaded) 
microbubbles/ml. The 400 nm increase in average diameter of the bubbles upon 
loading with liposomes strongly indicates the formation of a single liposome layer at 
the microbubble surface as the hydrodynamic diameter of a single liposome is about 
200 nm.  
3.2 Improving the liposome-loading of the microbubbles  
 Clearly, the more liposomes could be loaded onto the microbubble shell, the 
more drug could be released when the microbubble collapses. In a next step we 
evaluated whether the microbubble loading could be increased by using higher 
amounts of DSPE-PEG-SPDP lipids in the microbubble shell. We evaluated the 
amount of liposomes loaded per bubble through the use of bodipy-labeled liposomes 
and quantifying the fluorescence of the bodipy-liposome-loaded microbubbles 
through flow cytometry. Figure 3A clearly shows that the mean fluorescence per 
bubble increases upon (a) adding more liposomes to the mixture and (b) using higher 
amounts of DSPE-PEG-SPDP in the lipid mixture. Figure 3B shows Coulter Counter 
measurements on the corresponding bubbles and clearly indicates that upon using 
35% DSPE-PEG-SPDP the microbubbles become substantially larger which explains 
the increased loading capacity of these microbubbles as more surface space per 
bubble is available. We noticed that it is possible to incorporate even higher amounts 
of DSPE-PEG-SPDP-lipids in the bubbles, however, the resulting microbubbles were 
unstable. Hence, we concluded that the use of a 35% molar ratio of DSPE-PEG-
SPDP-lipids is optimal for liposome loading.  
 Figure 3: flow cytometry and coulter counter measurements of liposome-
loading with increased PEGylation: (A) Results of flow cytometry on bodipy-
liposome loaded microbubbles: mean fluorescence per bubble in function of the 
amount of bodipy-liposomes added to the lipid mixture. (B) Volume per microbubble, 
as measured by Coulter Counter, in function of the amount of DSPE-PEG-SPDP 
used in the lipid mixture. 
3.3 Behavior of liposome-loaded microbubbles in plasma  
Clearly, successful ultrasound triggered drug release assumes that the 
microbubbles keep the drug as long as ultrasound energy is not applied. To judge 
whether liposome-loaded microbubbles remain stable once injected in plasma and do 
not release drug due to interactions with plasma components, we performed flow 
cytometry measurements on microbubbles loaded with bodipy-liposomes dispersed 
in human platelet poor plasma (Figure 4). We could not observe significant 
differences in the fluorescence of liposome-loaded microbubbles dispersed in 
respectively plasma and buffer indicating that liposome-loaded microbubbles remain 
stable in plasma. Hence we predict that the liposomes will remain bound to the 
bubbles after injection in the bloodstream, at least as long as they are not exposed to 
ultrasound.  
 
Figure 4: flow cytometry assessment of the stability of liposome-loading 
in plasma: Results of flow cytometry on bodipy-liposome-loaded microbubbles: 
mean fluorescence per bubble in function of the amount of bodipy-liposomes added 
to the lipid mixture. 
3.4  Aspecific interactions between the liposomes and the microbubbles  
Subsequently we evaluated whether liposomes can stick (i.e. become 
aspecifically bound) to the microbubbles. Therefore we prepared microbubbles with 
DSPE-MPEG lipids without functional end groups, thereby avoiding covalent binding. 
Figure 5A shows the fluorescence of non-functionalized microbubbles exposed to 
bodipy-liposomes, as measured through flow cytometry. Clearly, liposomes bind 
aspecifically to the microbubbles. However, as could be expected, liposome loading 
of the microbubbles through covalent interactions enables significantly higher 
loading, which is of interest for use in drug delivery. One could speculate about the 
nature of the aspecific interactions between the liposomes and microbubbles. As 
schematically illustrated in Figure 5B, entanglements between PEG-chains on the 
liposomes and microbubbles may contribute to this phenomenon.  
 
Figure 5: flow cytometry assessment of aspecific liposome-loading: (A) Results 
of flow cytometry on bodipy-liposome loaded microbubbles: mean fluorescence per 
bubble in function of the amount of bodipy-liposomes added to the lipid mixture. The 
micobubbles contained 35 mol% DSPE-PEG-SPDP, the liposomes contained 
respectively 35% DSPE-mPEG or DSPE-PEG-MALEIMIDE. (B) Schematical 
depiction of specific (a) and aspecific (b) binding of the liposomes to the 
microbubbles through PEG-entanglements. 
3.5 Coulter Counter measurements gain further insight in the amount of 
liposomes loaded 
Although flow cytometry experiments revealed clear information on the loading 
of the microbubbles with liposomes, it remained impossible to estimate the number of 
liposomes loaded per microbubble. This information is of interest as it defines the 
drug dose which can be loaded on the microbubbles‟ surface. We reasoned that 
measuring the increase in volume of a microbubble upon loading it with liposomes 
(defined as “liposome volume per bubble”) in equation (2)) could give us valuable 
information. Dividing this “liposome volume per bubble” by the volume of one 
liposome allows us to estimate this number. Figure 6 shows the results of these 
experiments. For microbubbles with covalently attached liposomes we estimated that 
between 600 and 1300 liposomes can be loaded on the microbubbles‟ surface, which 
is significantly higher than the number which can be loaded through aspecific 
interactions. These data confirm the results obtained by Klibanov et al. [26] where is 
claimed that approximately 2000 liposomes with a diameter of 0.1µm can be bound 
to one bubble with a diameter of 2.5µm. However the number of 600-1300 liposomes 
per bubble is based on a volumetric measurement with the Coulter Counter. 
Interestingly, the results obtained through Coulter Counter measurements confirm the 
data observed in Figure 5A which were obtained through flow cytometry.  
 Figure 6: Estimation of the number of liposomes per bubble: Estimated number 
of liposomes per microbubble (containing 35 mol% DSPE-PEG-SPDP) as measured 
by Coulter Counter. 
 
3.6 Ultrasound induced DOX release from DOX-liposome-loaded 
microbubbles  
 Next we evaluated whether applying ultrasound on the DOX-liposome 
microbubble results in the release of DOX from the liposomes. As DOX encapsulated 
in liposomes has a lower fluorescence intensity than the corresponding amount of 
freely dissolved DOX, an increase in fluorescence could be expected upon applying 
ultrasound to the DOX-liposome loaded microbubbles. Figure 7 shows a significant 
increase in fluorescence when liposome-loaded microbubbles are subjected to 
ultrasound, which indicates that free doxorubicin is released from the liposomes after 
insonation.  
 Figure 7: Fluorimetric analysis of ultrasound induced free DOX release: 
Fluorescence intensity of DOX (expressed as relative light units (RLU)) significantly 
increases when liposome loaded microbubbles are subjected to ultrasound, 
indicating that DOX leaks out of destroyed liposomes after ultrasound treatment. 
3.7 Biological efficacy of DOX-loaded liposome bubbles treated with 
ultrasound 
In a next step we evaluated the tumor cell killing efficacy of DOX-liposome 
loaded microbubbles. Figure 8B shows the results of an in vitro cytotoxicity assay 
using different cell killing strategies. Clearly, ultrasound treatment of DOX-liposome 
loaded microbubbles (white bars) results in a significantly stronger killing of the cells. 
The x-axes in Figure 8B indicates the concentration of DOX in the Opticells™. Note 
that a higher DOX concentration was obtained through the use of microbubbles 
which were more loaded with DOX-liposomes (i.e. the number of DOX-liposome 
loaded microbubbles per Opticell™ was constant). Clearly, the „heavier‟ the 
microbubbles are loaded with DOX-liposomes the more cytotoxic they are. 
Importantly, without ultrasound DOX-liposome loaded microbubbles do not kill cells 
(dark gray bars in Figure 8B). As the DOX-liposome loaded microbubbles are not 
cytotoxic as long as they are not subjected to ultrasound, we suggest that such 
bubbles in combination with ultrasound may allow targeted release of DOX. We 
would like to note that, as the cytotoxicity experiments were done on a cell 
monolayer, cells were occasionally (physically) removed from this layer due to the 
ultrasound energy or the microbubbles treatment itself. This could induce false 
positive results in the cytotoxity experiments, although microbubble concentrations 
are used that induced a minimal cell displacement as verified microscopy (data not 
shown). The bars in Figure 8A show that at microbubble concentrations used in the 
experiments there was no significant killing of the cells due to the microbubble 
destruction itself; the observed cytotoxicity was similar to that observed with the blank 
(optimem).  
 
Figure 8: Viability measurements on melanoma cells: (A) Effect of microbubbles 
alone in presence of ultrasound on melanoma cell viability compared to no treatment 
(optimem). (B) Viability of melanoma cells after treatment with DOX-liposome loaded 
microbubbles, with ultrasound treatment (light gray bars), DOX-liposome loaded 
microbubbles without ultrasound treatment (dark gray bars) and DOX-liposomes 
alone, were measured using augmenting amounts of DOX-liposomes in an Opticell™ 
plate.  
 
3.8 Can dose reduction be achieved with DOX-liposome loaded 
microbubbles? 
 In the experiments in Figure 8 the DOX-liposome loaded microbubble 
dispersions did still contain an amount of free DOX-liposomes as it was 
experimentally difficult to separate free liposomes from the microbubbles. We were 
especially interested in the cell killing properties of the DOX-lipsosome loaded 
microbubbles themselves. We described above that between 600 and 1300 
liposomes can be bound per microbubble. Therefore we prepared a DOX-liposome 
microbubble dispersion using an amount of DOX-liposomes which is expected to 
become fully loaded on the microbubbles. One can calculate that, when the 
microbubbles are loaded with this amount of liposomes, approximately 5 µg of DOX 
is loaded on the microbbubbles present in a 1 mL dispersion. Under these conditions 
we performed the cytotoxicity measurements, which results in a DOX-concentration 
of 0.5 µg/ml in the Opticells™ after applying the DOX-liposome microbubble 
dispersion to the cells. Figure 9 compares the cell killing at a DOX concentration of 
0.5 µg/ml in the Opticells™, respectively when free DOX and DOX-liposome 
microbubble dispersion (without free DOX-liposomes) were applied. Despite the very 
low DOX-concentration in the Opticells™, DOX-liposome loaded microbubbles were 
clearly cytotoxic (in case ultrasound was applied). In contrast, free DOX did not 
cause any significant tumor cell death. Our results indicate that very low amounts of 
doxorubicin can become significantly effective when loaded onto microbubbles and 
exposed to ultrasound. An interesting observation towards the delivery of DOX as a 
lower dose may become sufficient in the treatment of patients.  
 
Figure 9: Viability measurements on melanoma cells with reduced dose: 
Viability of melanoma cells after exposure to respectively DOX-liposome loaded 
microbubbles (with and without ultrasound (US) treatment) and free DOX. The DOX- 
concentration in the wells was 0.5 µg/ml. Note that in these experiments we did not 
expect free DOX-liposomes to be present in the DOX-liposome loaded microbubble 
dispersion.  
4 DISCUSSION 
 In this paper we show that it is possible to design a safe and simple system for 
ultrasound guided drug delivery and we show that this system is very efficient in vitro, 
even when low amounts of model drug (DOX) are used. However, these in vitro 
experiments were performed in an ideal setting, because microbubbles were 
contacting the melanoma cells while sonicated, which probably leads to a more 
efficient sonoporation. In this respect, one could speculate on how to apply this 
system in an in vivo setting. Since microbubbles are relatively large particles, they will 
not pass the endothelial barrier in the tumor tissue, hence drug release has to occur 
in the blood vessels. The possible future clinical application of this system, will 
depend on how efficient the drug will penetrate the tissue under ultrasound 
application. Fortunately it has been recently shown that ultrasound and microbubbles 
can lead to a permeabilization of the endothelial barrier in (tumor) tissue which 
causes extravasation of coinjected molecules/drugs [27], other studies prove that 
ultrasound and microbubbles can even cause a local opening of the Blood Brain 
Barrier (BBB) [28]. In our measurements we have clearly shown that active 
compound is released out of the liposomes after implosion of the microbubbles, this 
release of free DOX can diffuse into the tissue after disruption of the endothelial 
barrier and can have a fast effect on the tumor cells. Furthermore, it is likely that not 
every liposome is destructed after ultrasound insonation, but is released in the 
surrounding environment. These liposomes can also be delivered into the tissue after 
endothelial barrier disruption. Another mechanism of tumor killing in vivo can be the 
specific killing of the endothelial cell layer directly contacting the microbubbles that 
are affected by the ultrasound. This mechanism is directly comparable with the in 
vitro experiments performed in this paper. The specific killing of endothelial cells will 
impair blood flow in the tumor and induce necrosis of the tumor. To even improve 
contact between these endothelial cells and the liposome-loaded microbubble a 
targeting ligand might be introduced in the system. The use of liposome-loaded 
microbubbles will in the end allow killing of tumor cells using less drug, because the 
drug will only be delivered where and when ultrasound is applied. Furthermore, future 
in vivo experiments with this system will have to answer the question whether the 
efficiency of the therapy will be improved too, if sonoporation allows direct delivery of 
the drug in endothelial cells and increased uptake in tumor cells. 
 Another issue which is still prone to discussion is the drug dose which can be 
maximally loaded on and thus delivered by the microbubbles. A microbubble is 
relatively small, which limits the space for drug loading. We believe that binding (drug 
containing) vesicles (like liposomes) on the surface of the bubbles maximizes the 
amount of drug that can be loaded. From this point of view this strategy may be an 
advantage when compared with other approaches reported to load microbubbles with 
drugs, like e.g. ones which load the drug into an inner oil layer or in the bubble shell 
itself [17,18]. Though we showed that approximately 600 to 1300 liposomes can be 
bound per single microbubble the amount of DOX which becomes loaded in this way 
still remains rather limited. The loading may be further improved by applying multiple 
layers of liposomes around the microbubbles. The materials reported here can only 
be further clinically evaluated provided one can overcome the low drug loading 
obstacle. Nowadays cancer patients are treated with a relatively high dose of 
DOXYL™, i.e. 40-50 mg DOX per injection. Designing drug-loaded microbubbles 
which would allow such a high DOX dosing is highly likely impossible unless really 
high amounts of bubbles (in the order of 1 x 1013 bubbles/ml) could be injected. 
However, considering the targeted and more efficient delivery of DOX when 
ultrasound and DOX-liposome loaded bubbles are used, we believe that such high 
DOX-doses might be no longer necessary, which may also reduce the severe side-
effects of DOX-therapy in particular and chemotherapy in general.  
Since apparati suitable for in vivo ultrasound assisted drug delivery that are able to 
deliver ultrasound into a focal spot deep into the tissue are allready under full 
development [29], the clinical evaluation of the drug-loaded microbubbles reported in 
this paper will smoothly move on and hopefully make it from bench to bedside. 
5 CONCLUSIONS 
This paper showed that that DOX-liposome loaded microbubbles can be obtainbed 
through self-assembly of (functionalized) phospholipids, drug-loaded liposomes and 
perfluorobutane gas. Importantly, this single step process results in a material which 
meets all criteria for clinical applicability: (a) no immunogenic compounds are used; 
(b) sterilization can easily be achieved through straightforward techniques and (c) 
adequate amounts of liposomes can be stabily loaded on the surface of the bubbles. 
Through flow cytometry and Coulter Counter measurements we showed a maximal 
loading of the microbubbles with liposomes when the lipid shell of the microbubbles 
was composed of 35 mol% of DSPE-PEG-SPDP, resulting in approximately 600 to 
1300 liposomes bound per single microbubble. Importantly, the liposomes remained 
bound to the mirobubbles' surface upon incubation in plasma, being a clear 
requirement for clinical application. Ultrasound induced microbubble collapse clearly 
induced the release of DOX. When compared with free DOX and DOX-liposomes, we 
observed that DOX-liposome loaded microbubbles in combination with ultrasound 
showed a significantly stronger killing of cancer cells. It is our opinion that the DOX-
liposome loaded microbubbles described in this paper provide an opportunity for 
ultrasound targeted cancer therapy. 
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